Anteris Technologies Ltd (AVR.AX)
- Previous Close
23.00 - Open
23.45 - Bid 22.80 x 60900
- Ask 23.15 x 237300
- Day's Range
22.50 - 23.45 - 52 Week Range
15.58 - 24.38 - Volume
5,075 - Avg. Volume
18,448 - Market Cap (intraday)
437.034M - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-4.31 - Earnings Date Apr 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
Anteris Technologies Ltd, a structural heart company, designs, develops, and commercializes medical devices. The company manufactures and sells ADAPT, a regenerative tissue product. Its lead product is the DurAVRTM, a transcatheter heart valve for the treatment of aortic stenosis. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.
www.anteristech.comRecent News: AVR.AX
Performance Overview: AVR.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVR.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVR.AX
Valuation Measures
Market Cap
437.03M
Enterprise Value
408.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
86.36
Price/Book (mrq)
15.28
Enterprise Value/Revenue
99.37
Enterprise Value/EBITDA
-6.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-127.62%
Return on Equity (ttm)
-329.00%
Revenue (ttm)
4.11M
Net Income Avi to Common (ttm)
-67.33M
Diluted EPS (ttm)
-4.31
Balance Sheet and Cash Flow
Total Cash (mrq)
30.83M
Total Debt/Equity (mrq)
8.14%
Levered Free Cash Flow (ttm)
-30.37M
Research Analysis: AVR.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: AVR.AX
AVR.AX does not have Company Insights